Latest news with #JunFeng
Cision Canada
2 days ago
- Business
- Cision Canada
EnChannel Medical to Acquire Acutus Medical AcQMap™ Electrophysiology Assets
This acquisition significantly strengthens EnChannel's intellectual property portfolio by integrating key innovations in second- and third-generation non-contact mapping (NCM) technologies. These technologies form the foundation for full-chamber atrial fibrillation (AF) mapping – a critical capability for understanding AF mechanisms and delivering effective, personalized treatment. "This strategic acquisition accelerates our mission to visualize and treat AF with unprecedented efficiency and precision," said Jun Feng, CEO of EnChannel Medical. "By building on prior advancements and leveraging our proprietary technologies, we are shaping the future of persistent AF diagnosis and treatment." Contact and Non-Contact Mapping in Perspective Conventional contact mapping systems sequentially collect electrical signals by making physical contact with many small regions of cardiac tissue, generating regional maps of electrical activity over numerous beats that are gradually assembled into a composite view across the chamber surface. While effective for regular rhythms, it is time-consuming, and it cannot capture the full dynamics of irregular activation patterns, such as in AF, often averaging out critical details and reducing mapping accuracy and specificity. In contrast, non-contact mapping (NCM) reconstructs full-chamber electrical activity from cardiac signals sensed by numerous electrodes distributed within the atrial chamber cavity. NCM delivers a comprehensive, single-beat depiction of activation over the entire atrial chamber at every instance of time. This approach significantly improves mapping efficiency and preserves the dynamic patterns of both regular and complex, irregular rhythms, including AF. Acutus' AcQMap™ technology is a second-generation NCM platform that advanced beyond the first-generation voltage-to-voltage mapping (pioneered by Endocardial Solutions – now part of Abbott), and delivered improved spatial resolution and accuracy, using voltage-to-charge-density mapping. Advancing the Frontier of Non-Contact Mapping EnChannel's propriety Action Potential Mapping offers a third-generation breakthrough in NCM technology, with accurate reconstruction of both depolarization and repolarization dynamics. This fulfills a biophysical unmet need that remains in conventional mapping, which cannot address repolarization. Action Potential Mapping therefore approaches the real nature of cardiac conduction and enables comprehensive understanding of the mechanisms that initiate and maintain AF – laying the groundwork for precise, individualized treatment of persistent AF. "Many of us at EnChannel had essential roles in developing all three generations of non-contact mapping," said Graydon Beatty, CSO of EnChannel Medical. "Each generation informed and enabled the next one; from reproduction of the cardiac signal in the first; to resolving the physical electric source of the signal in the second; and now culminating in reconstruction of the physiologic action potential in the third, revealing the actual nature of cardiac conduction dynamics. This acquisition unites our history of requisite methods and resources across the generations, and advances a hybrid workflow of all modes of navigation, mapping, and visualization. We are poised and resolved to establish an electrophysiology ecosystem that uncovers the mechanisms of AF, optimizes patient-specific treatment, and improves clinical outcomes in persistent AF." About EnChannel Medical Founded in 2020 by a team of seasoned electrophysiology innovators from both the United States and China, EnChannel is developing a holistic platform that unifies magnetic-impedance navigation, intracardiac echocardiography, full-chamber 5D action-potential mapping, and mid-voltage (<1000 V) pulsed-field ablation to deliver safe and personalized treatment for patients with atrial fibrillation. EnChannel is well positioned to expand its global innovation and advance its mission to transform AF care through data-driven, patient-specific therapy solutions. For more information, visit and follow us on LinkedIn. EnChannel's mapping and ablation products are investigational devices and are limited by federal (or United States) law to investigational use. Media Contact Bradley Wegrzynowicz (610) 462-0197 [email protected] SOURCE EnChannel Medical Ltd.
Yahoo
01-05-2025
- Business
- Yahoo
EnChannel Medical Raises $82.2M in Oversubscribed Series-B Financing to Advance Full-Chamber 5D Atrial Fibrillation Mapping and Personalized Pulsed-Field Ablation Therapy
GUANGZHOU, China, May 1, 2025 /PRNewswire/ -- EnChannel Medical, a breakthrough innovator in cardiac electrophysiology, today announced the successful completion of an oversubscribed Series B financing, raising $82.2M (600M RMB). The round was co-led by Dragonball Capital and existing investor Lilly Asia Ventures (LAV), with continued strong support from Lapam Capital. This financing marks one of the largest private investments in China's medical device sector since 2023. EnChannel's previously completed its Series A round of $27.8M (195M RMB) in August 2023. Proceeds from the Series B round will accelerate product development and advance clinical registration trials both in China and internationally. "EnChannel's platform integrates full-chamber action-potential mapping with pulsed-field ablation to address long-standing unmet needs in atrial fibrillation treatment," said Jun Feng, CEO of EnChannel Medical. "We're grateful for the strong support from new and returning investors and encouraged by early clinical data from our ongoing studies. Key results were presented at the Heart Rhythm Society Meeting in San Diego, held April 24-27." About EnChannel MedicalFounded in 2020 by a team of seasoned electrophysiology innovators from both the United States and China, EnChannel is developing a holistic platform that unifies magnetic-impedance navigation, intracardiac echocardiography, full-chamber 5D action-potential mapping, and mid-voltage (<1000 V) pulsed-field ablation to deliver safe and personalized treatment for patients with atrial fibrillation. Headquartered in Guangzhou, with an R&D subsidiary in Irvine, California, EnChannel is well positioned to expand its global innovation and advance its mission to transform AF care through data-driven, patient-specific therapy solutions. For more information, visit and follow us on LinkedIn. The DePolar® Mapping System and the NanoAblate® PFA System are investigational devices and are limited by federal (or United States) law to investigational use. Media ContactBradley Wegrzynowicz(610) View original content to download multimedia: SOURCE EnChannel Medical Ltd. Sign in to access your portfolio
Cision Canada
01-05-2025
- Business
- Cision Canada
EnChannel Medical Raises $82.2M in Oversubscribed Series-B Financing to Advance Full-Chamber 5D Atrial Fibrillation Mapping and Personalized Pulsed-Field Ablation Therapy USA - English USA
GUANGZHOU, China, May 1, 2025 /CNW/ -- EnChannel Medical, a breakthrough innovator in cardiac electrophysiology, today announced the successful completion of an oversubscribed Series B financing, raising $82.2M (600M RMB). The round was co-led by Dragonball Capital and existing investor Lilly Asia Ventures (LAV), with continued strong support from Lapam Capital. This financing marks one of the largest private investments in China's medical device sector since 2023. EnChannel's previously completed its Series A round of $27.8M (195M RMB) in August 2023. Proceeds from the Series B round will accelerate product development and advance clinical registration trials both in China and internationally. "EnChannel's platform integrates full-chamber action-potential mapping with pulsed-field ablation to address long-standing unmet needs in atrial fibrillation treatment," said Jun Feng, CEO of EnChannel Medical. " We're grateful for the strong support from new and returning investors and encouraged by early clinical data from our ongoing studies. Key results were presented at the Heart Rhythm Society Meeting in San Diego, held April 24-27." About EnChannel Medical Founded in 2020 by a team of seasoned electrophysiology innovators from both the United States and China, EnChannel is developing a holistic platform that unifies magnetic-impedance navigation, intracardiac echocardiography, full-chamber 5D action-potential mapping, and mid-voltage (<1000 V) pulsed-field ablation to deliver safe and personalized treatment for patients with atrial fibrillation. Headquartered in Guangzhou, with an R&D subsidiary in Irvine, California, EnChannel is well positioned to expand its global innovation and advance its mission to transform AF care through data-driven, patient-specific therapy solutions. For more information, visit and follow us on LinkedIn. The DePolar® Mapping System and the NanoAblate® PFA System are investigational devices and are limited by federal (or United States) law to investigational use. SOURCE EnChannel Medical Ltd.
